Chemistry:MK-8189
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H22N6OS |
| Molar mass | 382.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.[1][2][3][4]
References
- ↑ Mukai, Yuki; Lupinacci, Robert; Marder, Stephen; Mackle, Mary; Snow-Adami, Linda; Voss, Tiffini; Smith, Sean; Egan, Michael (May 2022). "P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia". Biological Psychiatry 91 (9): S305. doi:10.1016/j.biopsych.2022.02.771.
- ↑ Smith, Sean; Uslaner, Jason; Kandebo, Monika; Hostetler, Eric; Raheem, Izzat; Layton, Mark; Gantert, Liza; Riffel, Kerry et al. (May 2022). "P546. Preclinical Characterization and Phase 1 Evaluation of the Tolerability, Pharmacokinetics, and Enzyme Occupancy of MK-8189, a Novel PDE10A Inhibitor". Biological Psychiatry 91 (9): S309–S310. doi:10.1016/j.biopsych.2022.02.783.
- ↑ Layton, Mark E.; Kern, Jeffrey C.; Hartingh, Timothy J.; Shipe, William D.; Raheem, Izzat; Kandebo, Monika; Hayes, Robert P.; Huszar, Sarah et al. (26 January 2023). "Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia". Journal of Medicinal Chemistry 66 (2): 1157–1171. doi:10.1021/acs.jmedchem.2c01521. PMID 36624931.
- ↑ "MK-8189: A Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia". Synfacts 19 (4): 0410. April 2023. doi:10.1055/s-0042-1752651.
 |  |
